Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Latest News — Page 15

ICU clinician model comparison

Artificial Intelligence And Machine Learning

Hybrid Models Outperform Standalone AI or Clinicians in ICU Predictions

What if blending ICU clinician models delivers the best patient outcomes?

A new analysis comparing staffing approaches reveals that hybrid models—merging physician-led oversight with advanced practice provider expertise—outperform traditional structures in efficiency, cost, and care quality.

Explore the full findings and see how this evidence can guide your ICU strategy.
#SyenzaNews #healthcare #HealthcareInnovation #innovation #strategicplanning

Syenza TeamRead ›
ublituximab portugal approval

Cost Effectiveness Analysis

Portugal Funds Briumvi for MS Only After First-Line Failures

❓ How is Portugal’s approval of ublituximab reshaping access to multiple sclerosis therapies?

The decision introduces new restrictions that could limit patient options and complicate market entry for innovative MS treatments.

Explore the full implications for healthcare access and regulatory strategy.
#SyenzaNews #pharmaceuticals #HealthcareInnovation #MarketAccess #healthcarepolicy

Syenza TeamRead ›
statutory health insurance reform

Clinical Guidelines And Protocols

Stephan Pilsinger: How a Practising GP Is Shaping Germany’s Prevention-First Health Reforms

How can statutory health insurance reforms put prevention at the center of care?

New updates prioritize proactive health measures to improve outcomes, reduce long-term costs, and strengthen system sustainability.

Explore the key changes reshaping healthcare policy.
#SyenzaNews #healthcare #HealthcareInnovation #healthcarepolicy #innovation

Syenza TeamRead ›
SION-719 trial results

Clinical Practice

Sionna Pivots to Dual Combo After SION-719 Misses in Cystic Fibrosis Trial

📉 Disappointing results from the SION-719 cystic fibrosis trial – what does this mean for future drug development?

The study failed to meet key endpoints, underscoring ongoing challenges in advancing new therapies for CF patients.

Read the full breakdown of the findings and their implications.
#SyenzaNews #clinicaltrials #drugdevelopment #innovation #MarketAccess

Syenza TeamRead ›
PRIME scheme eligibility

Clinical Practice

EMA PRIME Scheme Stays Selective, Granting Access to Two Gene Therapies in July 2026

Is the PRIME scheme growing more exclusive for innovative medicines?

Eligibility criteria for the European Medicines Agency’s PRIME scheme remain highly selective in 2026, underscoring the rigorous standards required to secure early regulatory support for therapies addressing unmet medical needs.

Discover what this means for drug developers and patients.
#SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #MarketAccess

Syenza TeamRead ›
INFARMED Datroway funding rejection - breast cancer HTA decision

Clinical Guidelines And Protocols

Infarmed Datroway Funding Rejection for HR+ Breast Cancer

Portugal’s INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.

Syenza TeamRead ›
India SACU trade agreement

Health Policy

India, SACU Revive Trade Pact Talks at BRICS with Focus on Pharma and Minerals

🚀 How is the India-SACU trade agreement unlocking new pharma growth?

This landmark deal is expanding market access, cutting tariffs, and accelerating exports for Indian pharmaceutical companies across Southern Africa.

Discover the strategic opportunities it creates for the sector.

#SyenzaNews #pharmaceuticals #globalhealth #innovation #MarketAccess

Syenza TeamRead ›
local pharma procurement policy

Clinical Practice

COSATU Urges Government to Favour Local Pharma Makers Amid Job Losses

Can local procurement policies turn the tide for South Africa’s pharmaceutical jobs?

A strategic shift toward prioritizing local pharma manufacturing could safeguard thousands of positions while strengthening supply chain resilience and economic growth. This approach balances cost considerations with long-term industrial development in the sector.

Explore the full analysis.
#SyenzaNews #pharmaceuticals #MarketAccess #healthcarepolicy

Syenza TeamRead ›
Novo Nordisk profit guidance

Diseases

Novo Nordisk Lifts 2026 Guidance on Oral Wegovy Demand

📈 How is the GLP-1 surge reshaping pharmaceutical forecasts?

Novo Nordisk has raised its full-year profit guidance, propelled by explosive demand for its GLP-1 therapies in diabetes and obesity care.

Discover the market forces behind this momentum.
#SyenzaNews #pharmaceuticals #biotech #innovation #MarketAccess

Syenza TeamRead ›
Portuguese surgeon disciplinary review

Europe

Portuguese Army Opens Disciplinary Proceedings Against Former SNS Director

⚠️ What breaches were uncovered in a Portuguese surgeon’s disciplinary review?

A recent investigation has exposed serious lapses in clinical standards and regulatory compliance, raising fresh questions about accountability in surgical practice.

Read the full analysis to see what this means for patient safety and oversight.
#SyenzaNews #regulatoryaffairs #HealthcareInnovation #governance #innovation

Syenza TeamRead ›
South Africa lenacapavir manufacturing

Clinical Practice

South Africa Shortlists Local Firms to Produce Lenacapavir HIV Prevention Shot

How is South Africa advancing local production of cutting-edge HIV treatments?

The country has shortlisted manufacturers for Lenacapavir, paving the way for greater domestic capacity, improved access, and stronger pharmaceutical supply chains across the region.

Explore how this step supports broader drug development goals.
#SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

Syenza TeamRead ›
NHS ambient scribing guidance and MHRA AI voice technology regulation

Artificial Intelligence And Machine Learning

NHS England Clarifies Ambient Scribing Rules with MHRA Input

✨ How is the NHS using generative AI to slash documentation time and costs?

New guidance is helping clinicians cut admin burdens while improving efficiency across care pathways.

Discover the practical impact and key recommendations.

#SyenzaNews #AIinHealthcare #digitalhealth #ai #DigitalTransformation

Syenza TeamRead ›
quantum alzheimer blood test

Alzheimer's Disease

Quantum Blood Test Shows Promise for Early Alzheimer’s Detection

🧬 Could a quantum-powered blood test detect Alzheimer’s years earlier?

This breakthrough combines advanced quantum sensing with a simple blood draw to identify the disease at its earliest stages, opening new doors for timely intervention and care.

Explore how this innovation could reshape diagnostics.

#SyenzaNews #biotechnology #precisionmedicine #innovation #ai

Syenza TeamRead ›
integrated care in Canada - Syenza News

Clinical Guidelines And Protocols

Why Integrated Care in Canada Stalls — and Walter Wodchis’s Blueprint to Fix It

Is integrated care in Canada losing momentum? Walter Wodchis’ blueprint outlines a practical path to coordinated, patient-centered services, yet progress has stalled amid structural and policy barriers. This analysis explores the key challenges and what’s needed to move forward. Read the full breakdown to see how Canada can get integrated care back on track. #SyenzaNews #HealthcareInnovation #healthcare #innovation #healthcarepolicy

Syenza TeamRead ›
Zorgverzekeringsfonds operating deficit

Big Data Analysis

Dutch health fund projected to post €1.34bn deficit in 2026 after three surplus years

Is the Dutch health insurance fund heading back into the red?

Projections show the Zorgverzekeringsfonds returning to an operating deficit in 2026, raising fresh questions about long-term sustainability and the balance between premiums, benefits, and public spending.

Read the full analysis to see what this means for healthcare financing.
#SyenzaNews #healthcare #HealthEconomics #MarketAccess #healthcarepolicy

Syenza TeamRead ›
PB016 biosimilar application

Biologics And Biosimilars

FDA and EMA Accept Fresenius Vedolizumab Biosimilar for Review

How are biosimilar applications accelerating access across the US and EU?

Recent regulatory progress is streamlining approvals and expanding competition in biologic markets, potentially lowering costs for patients and payers alike.

Explore what this means for drug development and market access.
#SyenzaNews #biotechnology #pharmaceuticals #MarketAccess #innovation

Syenza TeamRead ›